Alpha 2.0
Login Register
» Authors » Robert Ryall

Robert Ryall

Explore the profile of Robert Ryall including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 559
Followers 0
Related Specialties
Pediatrics
Allergy & Immunology
General Medicine
Top 10 Co-Authors
Thomas Papa
David H Lamb
Q Paula Lei
Patricia Cash
Mike Bybel
XinXing Cai
Helen Joseph
Peter Andersen
Ingrid Kromann
Gregory Gilmet
Published In
Pediatr Infect Dis J
J Infect Dis
Clin Diagn Lab Immunol
Arch Pediatr Adolesc Med
Vaccine
Affiliations
Soon will be listed here.
Recent Articles
1.
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination
Nemes E, Geldenhuys H, Rozot V, Rutkowski K, Ratangee F, Bilek N, et al.
N Engl J Med . 2018 Jul; 379(2):138-149. PMID: 29996082
Background: Recent Mycobacterium tuberculosis infection confers a predisposition to the development of tuberculosis disease, the leading killer among global infectious diseases. H4:IC31, a candidate subunit vaccine, has shown protection against...
2.
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial
Geldenhuys H, Mearns H, Miles D, Tameris M, Hokey D, Shi Z, et al.
Vaccine . 2015 Jun; 33(30):3592-9. PMID: 26048780
Background: New, more effective vaccines to prevent tuberculosis (TB) disease are needed urgently. H4:IC31 is an investigational vaccine that contains a fusion protein of the immunodominant antigens TB10.4 and Ag85B,...
3.
Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs
Bernard M, Barban V, Pradezynski F, De Montfort A, Ryall R, Caillet C, et al.
PLoS One . 2015 Apr; 10(4):e0121518. PMID: 25837802
HSV-2 vaccine is needed to prevent genital disease, latent infection, and virus transmission. A replication-deficient mutant virus (dl5-29) has demonstrated promising efficacy in animal models of genital herpes. However, the...
4.
Safety and immunogenicity of a meningococcal (Groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine in healthy children aged 2 to 10 years in Chile
Lagos R, Papa T, Munoz A, Ryall R, Pina M, Bassily E
Hum Vaccin . 2006 Oct; 1(6):228-31. PMID: 17012878
Immune responses to meningococcal conjugate (Menactra; MCV-4) and plain polysaccharide (Menomune-A/C/Y/W-135; PSV-4) vaccines against serogroups A, C, Y, and W-135 were assessed in 220 of 1037 Chilean children aged 2...
5.
Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents
Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel M, et al.
Arch Pediatr Adolesc Med . 2005 Oct; 159(10):907-13. PMID: 16203934
Objective: A meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4; Menactra; Sanofi Pasteur Inc, Swiftwater, Pa) was developed to improve the profile of currently licensed...
6.
Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children
Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, et al.
Pediatr Infect Dis J . 2005 Jan; 24(1):57-62. PMID: 15665711
Background: A quadrivalent meningococcal diphtheria conjugate vaccine (MCV-4) has been developed to provide T-cell dependent immune responses against 4 major disease-causing serogroups (A, C, Y, W-135). Methods: In a comparative,...
7.
LC/MS characterization of meningococcal depolymerized polysaccharide group C reducing endgroup and internal repeating unit
Cai X, Lei Q, Lamb D, Shannon A, Jacoby J, Kruk J, et al.
Anal Chem . 2004 Dec; 76(24):7387-90. PMID: 15595884
Hydrogen peroxide has been used to cleave the native Neisseria meningiditis polysaccharide (PS) from mega-Dalton molecular weight to a smaller size (approximately 20 kDa) depolymerized polysaccharide. The polysaccharide was examined...
8.
Quantification of residual EDU (N-ethyl-N'-(dimethylaminopropyl) carbodiimide (EDC) hydrolyzed urea derivative) and other residual by LC-MS/MS
Lei Q, Lamb D, Shannon A, Cai X, Heller R, Huang M, et al.
J Chromatogr B Analyt Technol Biomed Life Sci . 2004 Nov; 813(1-2):103-12. PMID: 15556522
An LC-MS/MS method for determination of the break down product of N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide (EDC) urea derivative, EDU, has been developed and validated for monitoring the residual coupling reagents. Results indicate...
9.
Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants
Rennels M, King Jr J, Ryall R, Papa T, Froeschle J
Pediatr Infect Dis J . 2004 May; 23(5):429-35. PMID: 15131466
Background: Young children have the highest incidence of meningococcal infection. Approximately 50% of disease in United States children less than 2 years of age is caused by serogroups C and...
10.
Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera
Joseph H, Balmer P, Bybel M, Papa T, Ryall R, Borrow R
Clin Diagn Lab Immunol . 2004 Jan; 11(1):1-5. PMID: 14715537
Meningococcal serogroup-specific immunoglobulin G (IgG), IgG1, and IgG2 concentrations were assigned to three reference sera, CDC 1992, 89-SF, and 96/562, for meningococcal serogroups A, C, Y, and W135 via the...